Advertisement

Topics

Boehringer Ingelheim and Lilly Collaborate with University of Oxford to Investigate Empagliflozin in Chronic Kidney Disease

13:21 EDT 16 Apr 2018 | Speciality Pharma Journal

INGELHEIM, Germany & INDIANAPOLIS, Ind.–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. The study …

Original Article: Boehringer Ingelheim and Lilly Collaborate with University of Oxford to Investigate Empagliflozin in Chronic Kidney Disease

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim and Lilly Collaborate with University of Oxford to Investigate Empagliflozin in Chronic Kidney Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...